Recent advancements in pharmaceutical treatments and surgical guidelines characterize today's major health and medical developments.

A regulator-mandated study has confirmed that semaglutide is not associated with an increased risk of pancreatic cancer compared to other diabetes treatments.

The FDA has approved tavapadon as the first selective D1/D5 receptor agonist designed to treat adults suffering from Parkinson's disease.

Medical experts emphasize the necessity of tailoring menopausal hormone therapy based on route, dose, and duration to manage individual thrombotic risks.

Advancements in affordable genetic testing are revolutionizing the diagnosis and treatment of Inborn Errors of Immunity (IEIs), moving medicine beyond traditional care models.

A clinical trial indicates that patients with idiopathic pulmonary fibrosis achieve greater exercise endurance by utilizing single-leg cycling rather than traditional two-leg rehabilitation.

Research on rozanolixizumab in severe fibromyalgia cases suggests that while the drug may improve general health and function, it shows limited efficacy for pain and fatigue.

A new study reveals that kidney stone surgery durations exceeding 95 minutes correlate with a higher incidence of postoperative complications in elderly patients.

The use of JAK inhibitors for alopecia has received approval for adolescents aged 12-17, demonstrating significant scalp and facial hair regrowth in clinical trials.